USD 339.23
(0.0%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 121.29 Million EUR | -0.55% |
2022 | 121.96 Million EUR | 7.78% |
2021 | 113.16 Million EUR | -16.82% |
2020 | 136.03 Million EUR | 163.9% |
2019 | 51.55 Million EUR | 156.48% |
2018 | 20.09 Million EUR | 880.54% |
2017 | -2.57 Million EUR | -107.43% |
2016 | 34.64 Million EUR | 268.38% |
2015 | 9.4 Million EUR | -85.21% |
2014 | 63.59 Million EUR | 5.08% |
2013 | 60.52 Million EUR | -9.16% |
2012 | 66.62 Million EUR | 15.84% |
2011 | 57.51 Million EUR | -9.3% |
2010 | 63.41 Million EUR | 63.37% |
2009 | 38.81 Million EUR | 9.62% |
2008 | 35.4 Million EUR | 14.06% |
2007 | 31.04 Million EUR | 24.6% |
2006 | 24.91 Million EUR | 25.83% |
2005 | 19.79 Million EUR | 18.37% |
2004 | 16.72 Million EUR | -39.28% |
2003 | 27.54 Million EUR | -30.76% |
2002 | 39.78 Million EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | 47.33 Million EUR | 104.63% |
2024 Q2 | 47.33 Million EUR | 0.0% |
2023 FY | 121.29 Million EUR | -0.55% |
2023 Q2 | 75.03 Million EUR | 100.71% |
2023 Q3 | 23.26 Million EUR | -69.0% |
2023 Q4 | 23.13 Million EUR | -0.57% |
2023 Q1 | 37.38 Million EUR | -15.84% |
2022 Q1 | 38.77 Million EUR | -4.16% |
2022 Q2 | 77.54 Million EUR | 100.0% |
2022 Q3 | 22.19 Million EUR | -71.37% |
2022 Q4 | 44.42 Million EUR | 100.11% |
2022 FY | 121.96 Million EUR | 7.78% |
2021 Q4 | 40.45 Million EUR | 96.6% |
2021 FY | 113.16 Million EUR | -16.82% |
2021 Q2 | 72.7 Million EUR | 101.94% |
2021 Q1 | 36 Million EUR | -60.13% |
2021 Q3 | 20.57 Million EUR | -71.7% |
2020 FY | 136.03 Million EUR | 163.9% |
2020 Q2 | 47.15 Million EUR | 100.0% |
2020 Q1 | 23.57 Million EUR | -6.12% |
2020 Q4 | 90.31 Million EUR | 103.21% |
2020 Q3 | 44.44 Million EUR | -5.75% |
2019 Q2 | 13.21 Million EUR | 0.0% |
2019 Q4 | 25.11 Million EUR | 100.0% |
2019 FY | 51.55 Million EUR | 156.48% |
2019 Q3 | 12.55 Million EUR | -4.99% |
2019 Q1 | 13.21 Million EUR | 237.61% |
2018 Q3 | 3.91 Million EUR | -36.18% |
2018 FY | 20.09 Million EUR | 880.54% |
2018 Q2 | 6.13 Million EUR | 0.0% |
2018 Q1 | 6.13 Million EUR | 174.38% |
2018 Q4 | 3.91 Million EUR | 0.0% |
2017 Q3 | -8.24 Million EUR | -218.5% |
2017 Q2 | 6.96 Million EUR | 0.0% |
2017 Q4 | -8.24 Million EUR | 0.0% |
2017 FY | -2.57 Million EUR | -107.43% |
2017 Q1 | 6.96 Million EUR | -35.4% |
2016 Q4 | 10.77 Million EUR | 0.0% |
2016 Q1 | 6.54 Million EUR | -0.99% |
2016 FY | 34.64 Million EUR | 268.38% |
2016 Q3 | 10.77 Million EUR | 64.51% |
2016 Q2 | 6.54 Million EUR | 0.0% |
2015 Q2 | -1.91 Million EUR | 0.0% |
2015 FY | 9.4 Million EUR | -85.21% |
2015 Q4 | 6.61 Million EUR | 0.0% |
2015 Q3 | 6.61 Million EUR | 445.95% |
2015 Q1 | -1.91 Million EUR | -110.69% |
2014 Q1 | 13.9 Million EUR | -0.36% |
2014 FY | 63.59 Million EUR | 5.08% |
2014 Q3 | 17.88 Million EUR | 28.61% |
2014 Q4 | 17.88 Million EUR | 0.0% |
2014 Q2 | 13.9 Million EUR | 0.0% |
2013 Q1 | 16.3 Million EUR | 0.0% |
2013 FY | 60.52 Million EUR | -9.16% |
2013 Q3 | 13.95 Million EUR | -14.38% |
2013 Q2 | 16.3 Million EUR | 0.0% |
2013 Q4 | 13.95 Million EUR | 0.0% |
2012 FY | 66.62 Million EUR | 15.84% |
2011 FY | 57.51 Million EUR | -9.3% |
2010 FY | 63.41 Million EUR | 63.37% |
2009 FY | 38.81 Million EUR | 9.62% |
2008 FY | 35.4 Million EUR | 14.06% |
2007 FY | 31.04 Million EUR | 24.6% |
2006 FY | 24.91 Million EUR | 25.83% |
2005 FY | 19.79 Million EUR | 18.37% |
2004 FY | 16.72 Million EUR | -39.28% |
2003 FY | 27.54 Million EUR | -30.76% |
2002 FY | 39.78 Million EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
AstraZeneca PLC | 5.95 Billion USD | 97.963% |
Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 98.488% |
CSPC Pharmaceutical Group Limited | 830.91 Million USD | 85.402% |
Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 314.641% |
Novartis AG | 14.85 Billion USD | 99.183% |
PT Kalbe Farma Tbk. | 179.7 Million USD | 32.502% |